changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Argentina now the second South American country to offer TheraSphere™ treatment for
liver cancer patients
Brazil to be the first South American country to offer TheraSphere® treatment for
liver cancer patients
An estimated 500 patients per year in France could be eligible for treatment with TheraSphere®
BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Novate Medical Ltd. (“Novate”), a medical device company focused on the prevention of pulmonary embolism (PE) in patients at high risk of venous thromboembolic events.
Based on experience with 1000 patients over 15 years, the largest single-centre, prospective centre cohort of patients with HCC treated with Y90 glass microspheres
London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.
Mirada Medical Ltd, a global medical imaging software company, has signed a three-year master service agreement with BTG plc (LSE: BTG), a global specialist healthcare company. The agreement covers multiple software development projects to support BTG’s portfolio of interventional medicine products.
BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.
Study shows patients treated with TheraSphere® maintain quality of life throughout 90 day post-treatment period
BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology